NPS Pharmaceuticals (NPSP) received encouraging news when the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended the approval of the company’s hormone replacement therapy Natpara (rhPTH [1-84]). NPS Pharma’s candidate was recommended for long-term use to treat patients suffering from hypoparathyroidism, a rare disease caused by the deficiency/absence of parathyroid hormone, by 8 of the 13 panel members. The positive opinion rendered … Continue reading Biotech Stocks in News: NPS Pharmaceuticals’ Natpara Gets Positive Review, Stock Set For a High

Shares of Avanir Pharmaceuticals (AVNR) gained a massive 85.31% to close the trading session on Sep 15 at $12.49. The jump came on the back of encouraging data from a phase II study (n=220) on Avanir‘s AVP-923, which evaluated the safety, tolerability and efficacy of the candidate for treating agitation associated with Alzheimer’s disease. Data revealed that agitation was significantly reduced in patients treated with … Continue reading Biotech Stock Update: Avanir Pharmaceuticals Shoots Up Due to Positive Results

AbbVie (ABBV) was in the news last week thanks to its agreements with Infinity Pharmaceuticals (INFI) and Calico. Keryx Biopharmaceuticals (KERX) was also in the headlines – the company’s shares declined despite receiving FDA approval for its oral, ferric iron-based compound. Gilead (GILD) was in the news as well, once again due to its hepatitis C virus (HCV) treatment, Sovaldi. AbbVie was very active on … Continue reading Biotech Stocks Update: A Review of the Biotech Stocks for the Week

Alexion Pharmaceuticals’ (ALXN) sole marketed product is Soliris (eculizumab). Soliris is available for the treatment of two rare genetic disorders – paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. As the company is entirely dependent on Soliris for growth, it should look to avoid any setback related to the product. However, the FDA seems to be far from pleased with Soliris’ manufacturing facility at Rhode … Continue reading Biotech Stock Alexion to take a hit as fails tests

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized. Earlier this week, Amgen Inc (AMGN) announced the submission of a … Continue reading Biotech Stock News: Amgen Breaking New Ground

Shares of Gilead Sciences (NASDAQ GILD) dropped 1.4% to close the trading session on Sep 5 at $105.36 following a Bloomberg report claiming that the biopharmaceutical major will ink a licensing deal with generic players in order to make its blockbuster hepatitis C drug Sovaldi available in approximately 80 developing nations such as India and Pakistan at low cost. According to the report, Gilead is … Continue reading Biotech Stocks Review: Gilead Stocks see an Unexpected Drop